Login / Signup

Safety Profile of Paxlovid in the Treatment of COVID-19.

Bing LvXin GaoGuoqiang ZengHui GuoFaping Li
Published in: Current pharmaceutical design (2024)
This study indicates that the most common AEs reported with Paxlovid in post-marketing experience are consistent with the safety assessment of antiviral drugs. Even without emerging apparent safety concerns, the incidence of serious outcomes was unexpectedly high, and a few cases of potential new AEs occurred.
Keyphrases
  • coronavirus disease
  • sars cov
  • type diabetes
  • magnetic resonance imaging
  • magnetic resonance
  • metabolic syndrome
  • insulin resistance
  • replacement therapy